Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Bayer Healthcare Pharmaceuticals, Inc. and Celgene Corporation.

Cancer Summaries and Commentaries™: Report from San Diego on Advancements in Non-Hodgkin Lymphoma

Release Date: December 31, 2018
Expiration Date: December 31, 2019
Media: Internet - based

Activity Overview

This online Physicians’ Education Resource®, LLC activity, Cancer Summaries and Commentaries™: Report from San Diego on Advancements in Non-Hodgkin Lymphoma, is designed to update physicians on data presented at the American Society of Hematology Annual Meeting and Exposition, which took place December 1-4, 2018, in San Diego, CA. During this online activity, the program faculty, Prof. Gilles Salles and Nathan H. Fowler, MD, will each review 3 abstracts chosen as the most clinically relevant to facilitate integration of cutting-edge data into practice. For each abstract, a short summary of key clinical data is accompanied by expert perspectives that provide insight into how clinicians can apply these findings to their clinical practice to improve patient care.

Benefits of Participating

By participating in this exciting program, you will:

  • Listen to expert perspectives on integrating cutting-edge clinical trial data and real-world evidence into clinical practice for the treatment of patients with non-Hodgkin lymphoma (NHL)
  • Learn about recently reported clinical trial data with the potential to change NHL treatment paradigms
  • Identify key ongoing clinical trials for patients with NHL, including diffuse large B-cell lymphoma, follicular lymphoma, peripheral T-cell lymphoma, and marginal zone lymphoma

Acknowledgement of Commercial Support

This activity is supported by educational grants from Bayer Healthcare Pharmaceuticals, Inc. and Celgene Corporation.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.

Target Audience

This activity is directed toward medical oncologists and hematologists who treat patients with NHL. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the management of patients with NHL are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain clinical study design and major efficacy and safety endpoints of completed/ongoing trials being conducted in patients with NHL
  • Discuss recent clinical trial findings concerning novel compounds and strategies for patients with NHL
  • Discuss recent clinical trial evidence in the context of evolving treatment paradigms in the management of patients with NHL

Faculty, Staff, and Planners' Disclosures


Nathan H. Fowler
Nathan H. Fowler, MD
Associate Professor, Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: Celgene, Janssen, Roche, Verastem; Consultant: Celgene, Janssen, Roche, Verastem, TG Therapeutics

Gilles A. Salles
Gilles A. Salles, MD, PhD
University Professor
Head of Hematology
Claude Bernard University of Lyon
Hospices Civils de Lyon
Lyon, France

Disclosures: Advisory Board/Consulting/Educational Events: AbbVie, Amgen, BMS, Celgene, Gilead, Epizyme, Janssen, Karyopharm, Kite, Merck, Morphosys, Novartis, Roche, Servier, Takeda

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By